Sign in

You're signed outSign in or to get full access.

TH

TENET HEALTHCARE (THC)·Q4 2025 Earnings Summary

Tenet Previews Strong FY2025, Closes $1.9B Conifer Transaction

February 2, 2026 · by Fintool AI Agent

Banner

Tenet Healthcare (NYSE: THC) announced a major strategic transaction and previewed strong FY2025 results ahead of their full earnings release on February 11, 2026. The company completed a transaction with CommonSpirit Health to regain 100% ownership of Conifer Health Solutions, its revenue cycle management subsidiary, while signaling that FY2025 Adjusted EBITDA will land at the upper end of the $4.47B-$4.57B guidance range .

The announcement caps a year of consistent operational outperformance. Tenet raised guidance three times in 2025, with cumulative increases of $445M (11%) from initial expectations .


What Happened With Conifer?

Tenet completed a transaction with CommonSpirit Health (formerly Catholic Health Initiatives) to end their 23.8% ownership stake in Conifer Health Solutions, Tenet's revenue cycle management business .

Transaction Summary

Key Transaction Terms :

ItemValue
Total Payments to Tenet$1.9B over 3 years
Equity Redemption$540M paid to CommonSpirit for 23.8% stake
Effective DateJanuary 1, 2026
Balance Sheet Impact-$885M in NCI/liabilities
APIC Impact+$305M
Service ContinuationConifer serves CommonSpirit through end of 2026

CEO Saum Sutaria noted that "this milestone gives Tenet greater flexibility to support Conifer's long-term potential" and that Conifer will "expand its investments in artificial intelligence, automation and global operating capabilities" .

FintoolAsk Fintool AI Agent

Did Tenet Beat FY2025 Guidance?

Yes. Tenet previewed that FY2025 Adjusted EBITDA will be at the upper end of their $4.47B-$4.57B guidance range . This represents:

  • +$445M (+11%) from initial guidance of $3.98B-$4.18B set in February 2025
  • ~13% growth over FY2024's $4.0B Adjusted EBITDA

Guidance Evolution in 2025:

DateEventEBITDA Guidance (Midpoint)
Feb 2025Initial guidance $4.075B
Q2 2025First raise $4.125B
Q3 2025Second raise $4.52B
Feb 2, 2026Preview Upper end (~$4.55B+)

Management attributed the strong performance to "strong same store revenue growth and disciplined expense management" .


What Changed From Last Quarter?

Q3 2025 Results Recap (reported October 28, 2025):

MetricQ3 2025YoY Change
Revenue $5.3B+5.7%
Adjusted EBITDA $1.1B+12%
EBITDA Margin 20.8%+170bps
Free Cash Flow YTD $2.16B+22%

Q3 2025 Beat/Miss vs Consensus:

MetricActualConsensusSurprise
Revenue$5,289M$5,248M+0.8%*
EPS (Normalized)$3.70$3.35+10.5%*
EBITDA$1,099M$1,028M+6.9%*

*Values retrieved from S&P Global

Tenet has beaten EBITDA consensus for four consecutive quarters heading into Q4.


How Did the Stock React?

THC shares closed at $189.28 on January 30, 2026, ahead of the February 2 announcement. The stock is:

  • -15% from 52-week high of $222.82
  • +72% from 52-week low of $109.82
  • Trading at a market cap of ~$16.6B

The aftermarket quote following the announcement showed the stock at $186.69, down modestly (-1.4%), suggesting the market may have largely priced in strong results heading into the full earnings release .

FintoolAsk Fintool AI Agent

What Did Management Say?

CEO Saum Sutaria, M.D. on performance:

"We continue to deliver strong revenue growth, improved margins and attractive free cash flow as a result of effective execution of our strategies."

On the CommonSpirit transaction:

"CommonSpirit worked closely with us to structure a mutually beneficial transaction that reflects our longstanding partnership and commitment to the joint venture... The transaction will enable a thoughtful, collaborative transition over the coming year."

CommonSpirit CFO Michael Browning:

"Conifer has been a strong and reliable revenue cycle partner since 2012, bringing consistency to a previously fragmented environment... Conifer meaningfully contributed to these hospitals achieving 100% of their cash collection goals."


What's the 2026 Outlook?

Management provided preliminary color on 2026 during the Q3 2025 call :

Positives:

  • Healthy patient demand supporting same-store volume growth
  • USPI expected to deliver same-store revenue growth in line with long-term targets (3-6%)
  • Freestanding ASC rates insulate USPI from site neutrality regulatory changes
  • Conifer now 100% owned — incremental 2026 earnings from eliminated NCI distributions

Uncertainties:

  • Enhanced premium tax subsidies (ACA exchanges) still pending
  • State-directed Medicaid payment program approvals for 2026 pending
  • Tariff dynamics require continued management

Capital Allocation Priorities

Tenet's priorities remain unchanged :

  1. USPI M&A — Spent nearly $300M YTD in 2025, pipeline remains strong
  2. Hospital growth investments — Increased CapEx guidance to $875M-$975M (+$150M)
  3. Debt retirement/refinancing — Leverage at 2.3x EBITDA
  4. Share repurchases — $1.2B YTD through Q3 2025 (7.8M shares)

The Conifer transaction provides additional flexibility with $1.9B in cash payments over three years .


Key Risks and Concerns

  1. Regulatory uncertainty — ACA exchange subsidies and Medicaid payment programs still pending
  2. Conifer client transition — CommonSpirit services end 2026; revenue impact unclear
  3. Stock down from highs — Shares -15% from 52-week high despite strong results
  4. Forward estimates — Preliminary; actual Q4 results may differ

What to Watch February 11

Full Q4 and FY2025 results will be announced on February 11, 2026 . Key items to watch:

  • Final FY2025 EBITDA — Confirmation at upper end of range
  • FY2026 guidance — Initial targets for revenue, EBITDA, free cash flow
  • USPI growth trajectory — Same-store revenue and M&A pipeline
  • Conifer outlook — Impact of CommonSpirit transition on 2026-2027
  • Capital return — Share repurchase plans at current valuation
FintoolAsk Fintool AI Agent

Historical Performance

Quarterly EBITDA Beat/Miss History:

QuarterEBITDA ActualConsensusSurprise
Q4 2024$1,048M$1,012M+3.6%*
Q1 2025$1,163M$995M+16.9%*
Q2 2025$1,121M$992M+13.0%*
Q3 2025$1,099M$1,028M+6.9%*

*Values retrieved from S&P Global

Tenet has delivered EBITDA beats in all four quarters of 2025, with particularly strong outperformance in Q1 (+16.9%) and Q2 (+13.0%).


This analysis covers Tenet Healthcare's February 2, 2026 preliminary results announcement and Conifer transaction. Full Q4 and FY2025 results will be released February 11, 2026.